Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 7Endocrine 7Sarcoma 1Gynecologic 1Breast 1

Conditions

Sarcoma 200Osteosarcoma 74Sarcoma, Ewing 50Rhabdomyosarcoma 48Melanoma 42Neuroblastoma 38Gastrointestinal Stromal Tumors 35Neoplasms 34Neoplasm Metastasis 32Bone Neoplasms 32Colorectal Neoplasms 31Glioblastoma 29Breast Neoplasms 25Ovarian Neoplasms 24Wilms Tumor 23Rhabdoid Tumor 23Gliosarcoma 23Glioma 23Liposarcoma 22Carcinoma, Non-Small-Cell Lung 22Lymphoma, Non-Hodgkin 21Sarcoma, Kaposi 20Neurofibrosarcoma 20Carcinoma, Renal Cell 20Pancreatic Neoplasms 19Medulloblastoma 19Hepatoblastoma 19Desmoid Tumors 18Thyroid Neoplasms 17Lymphoma 17

Interventions

fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × Sarcoma × 90 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡